YEAR END 2025 EARNINGS REPORT February 13, 2026 Safe Harbor Statement All per-share amounts in this presentation are reported on a diluted basis. The only common equity securities that are publicly traded are common shares of Eversource Energy. The earnings discussion includes financial measures that are not recognized under generally accepted accounting principles (non-GAAP) referencing earnings and EPS excluding losses associated with our previous offshore wind investments, a loss on the pending sale of t ...

CAE (NYSE:CAE) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Speaker11Good day, ladies and gentlemen. Welcome to the CAE third quarter financial results for fiscal year 2026 conference call. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity for analysts to ask questions. To join the question queue, you may press Star, then one on your telephone keypad. Should you need assistance during the conference call ...

4Q2025 Supplemental Information FURNISHED AS OF FEBRUARY 12, 2026 - UNAUDITED FORWARD LOOKING STATEMENTS & RISK FACTORS This Supplemental Information report contains disclosures that are "forward-looking statements." Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "target," "intend," "plan," "estimate," "project," "continue," "should," "could," "budge ...

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [5][11] - Operating expenses decreased by $2.2 billion, or 30%, compared to the previous year [5] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - The company ended the year with $8.1 billion in cash and investments, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - For the fourth quarter, total revenue was $700 million, with $300 million from the U.S. and $400 million from international markets [11] - The U.S. revenue totaled $1.2 billion for the full year, while international revenue was $700 million [11] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, supported by the successful launch of mNEXSPIKE [12] - Internationally, operational performance and vaccination rates exceeded expectations, contributing to revenue growth [11] Company Strategy and Development Direction - The company aims for total revenue growth of up to 10% in 2026, primarily driven by international markets and local manufacturing agreements in the U.K. and Australia [15][16] - The company plans to launch mNEXSPIKE and its combination flu-COVID vaccine in Europe by the 2027 winter season, expanding its market share [20][21] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated approval of its flu vaccine in multiple countries [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting the challenges posed by regulatory uncertainty [6] - The company remains optimistic about its pipeline and expects continued clinical momentum, particularly in oncology and infectious disease programs [32][33] Other Important Information - The company has completed enrollment in several late-stage cancer studies and anticipates data readouts in 2026 [9][28] - A new Chief Development Officer, Dr. David Berman, will join the company, bringing extensive experience in clinical-stage immunotherapies [10] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [36][37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [42] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program, with a comprehensive data set already submitted [45][47] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [49][50] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [56][58] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [59][61]

Ingersoll Rand (NYSE:IR) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Speaker13Hello, and welcome to the Ingersoll Rand fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. I would now like to turn the conference over to Matthew Fort, Vice President, Investor Relations. You may begin.Speaker7Tha ...

Magna International (NYSE:MGA) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Speaker9Good morning, and thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the Magna International Fourth Quarter Full Year 2025 Results and 2026 Outlook. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question durin ...

Financial Data and Key Metrics Changes - Revenue for the fiscal quarter increased 105% year-over-year to $2.2 million, compared to $1.1 million for the same period last year, and a sequential increase of 21% from the previous quarter [15][16] - Gross profit increased to $300,000, compared to a gross loss of $200,000 for the same period last year [16] - Total operating expenses were reduced to approximately $6.9 million, down from $10.7 million for the same period last year, translating to a 36% reduction year-over-year [16][17] - Net loss attributed to common stockholders was $7.3 million, or a loss of $0.85 per share, compared to a net loss of $13 million, or a loss of $2.96 per share for the same period last year [18] Business Line Data and Key Metrics Changes - The core business, particularly the LungFit PH system, has seen significant adoption with over 45 hospitals now utilizing the first-generation system [5][6] - Customer retention exceeds 90%, with more than half of customers under multi-year agreements, indicating strong market acceptance [6] Market Data and Key Metrics Changes - The company has expanded its global distribution network for LungFit PH, now covering 40 countries, with new agreements in Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka [9] - The first sale to a VA Medical Center establishes a foothold in the largest healthcare network in the U.S., potentially leading to broader adoption [9] Company Strategy and Development Direction - The company has made a strategic decision to sell its Neuronas subsidiary, which is expected to provide up to $32.5 million in upfront payments and equity, strengthening its balance sheet for commercial execution [5][13] - The focus remains on expanding the utilization of the first-generation LungFit PH system while preparing for the anticipated FDA decision on the second-generation system, expected by the end of calendar 2026 [6][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, citing strong customer feedback and the dedication of the team as key factors for future growth [10] - The company is optimistic about the upcoming FDA approval process for the second-generation system, with ongoing positive interactions with the FDA [36] Other Important Information - The company completed a $5 million financing in January 2026, along with a $32 million equity line of credit, providing resources to support commercial execution and readiness for the second-generation LungFit PH system [14][19] - The company reported cash and cash equivalents of $17.8 million as of December 31, 2025, which is expected to provide a runway into calendar year 2027 [19] Q&A Session Summary Question: Sales process and penetrating healthcare systems - Management discussed the sales process for the VA system, highlighting the ease of access through the ECAT system, which allows for direct customer engagement without an RFP process [22][24] Question: Identifying target facilities for sales - The company has refined its commercial organization and uses prospecting tools and CRM systems to identify and engage potential customers effectively [26][27] Question: Length of the sales cycle - The sales cycle remains around 6-9 months, with efforts to streamline the process by identifying customer needs early [28][29] Question: Concerns about next-generation system affecting current sales - The focus is on the first-generation product, which is well-received, while discussions about the next-generation system are being kept separate for now [30][31] Question: FDA communications regarding the second-generation system - Management confirmed ongoing positive communications with the FDA and expressed confidence in meeting regulatory requirements [36] Question: International market wins and catalysts - Recent wins in international markets were highlighted, with customers beginning to reorder filters, indicating product stickiness [41] Question: Interest from XTL Biopharmaceuticals in Neuronas - The attractiveness of the Neuronas opportunity was attributed to strong scientific foundations and a clear path to human studies, with XTL providing necessary funding for advancement [48][50] Question: Cost of goods sold (COGS) performance - Long-term expectations for COGS are in the 60-70% range, with current levels expected to grow as revenue increases [53][54] Question: Impact of SG&A on revenue - Management discussed the sensitivity of sales cycles to increased SG&A, indicating that additional capital deployed in sales could translate into higher revenues [58]

Introduction Roger Hendriksen | Director, Investor Relations 2025 Year in Review Jeff Edwards | Chairman and Chief Executive Officer Financial Overview Jon Banas | Executive VP and Chief Financial Officer Strategic Overview and Outlook Jeff Edwards Creating Sustainable Solutions TOGETHER Fourth Quarter and Full Year 2025 Earnings Presentation February 13, 2026 Agenda Q & A 2 Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws, ...

Financial Data and Key Metrics Changes - The company reported GAAP earnings of $2.5 million for Q4 2025, with earnings available for distribution (EAD) at approximately -$500,000, leading to a per diluted share of $0.06 [8][9] - The common stock dividend yield is 8.7%, and the company has about $100 million in cash and liquidity [9][10] - The company is trading at roughly 50% of book value, with total equity in the vehicle at $300 million [6][7] Business Line Data and Key Metrics Changes - The company aims to grow its multifamily lending business, projecting production between $6 billion and $7 billion for the year, up from $1.7 billion previously [11] - The company has identified a pool of assets worth around $1 billion that could be added to the vehicle, which would lead to an immediate increase in earnings [30] Market Data and Key Metrics Changes - The commercial real estate sector is currently dislocated, with many REITs and BDCs trading poorly due to liquidity issues [9][10] - The company is optimistic about the office segment within commercial real estate, despite recent market volatility [14] Company Strategy and Development Direction - The company is focused on a potential recapitalization to enhance earnings and dividend growth, targeting earnings of $1.60 to $1.70 per share [5][11] - The strategy includes acquiring multifamily loans from its operating business, Genesis, and pursuing opportunistic investments in commercial real estate [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed a commitment to patience in executing their strategy, emphasizing the importance of market stabilization before proceeding with significant capital raises [10][15] - The management team highlighted the diversified earning streams within the company, which can mitigate risks associated with underperforming segments [14] Other Important Information - The company announced a reverse stock split of 6-to-1 to attract more interest in its stock [4] - The management team is exploring opportunities to become a Fannie Mae and Freddie Mac servicer or originator in the multifamily space [11][12] Q&A Session Summary Question: Will RPT receive a slice of the NOI from the Paramount transaction? - Management indicated that RPT has $50 million of the Paramount deal on its balance sheet, and earnings will be pro rata based on Rithm's performance [19] Question: Are there plans to increase loans from Genesis? - Management confirmed that Genesis is expected to produce $6 billion to $7 billion in loans, which will be accretive to RPT [20] Question: Is there a tolerance for finding other sources of capital? - Management acknowledged the possibility of bringing in third-party capital but emphasized the need to avoid dilutive actions [28] Question: What types of loans will RPT focus on? - Management stated that the primary focus will be on multifamily loans generated by Genesis, which are expected to be highly accretive [30] Question: Is there an opportunity to acquire from banks? - Management noted that banks are currently not significant sellers, but there is demand for the products that Genesis is producing [41]

Cameco (NYSE:CCJ) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Speaker8Thank you for standing by. This is the conference operator. Welcome to the Cameco Corporation Fourth Quarter 2025 Results Conference Call. As a reminder, all participants are in a listen-only mode, and the conference is being recorded. Following the introductory remarks, there will be an opportunity to ask questions. To join the question queue, you may press Star then one on your telephone keypad. Should you need assistance during ...